D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.